Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00204490 · ClinicalTrials.gov registry record · Phase 2
Soy Isoflavones and Breast Cancer Risk Reduction
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00204490: Completed Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
NCT00204490 is a Phase 2 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 197 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00204490, a Phase 2 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are currently unclear. Breast density has been considered as a breast cancer risk marker. We hypothesize that because isoflavones have estrogen-like activities, breast density and possibly bone density will be lower in women on soy-isoflavones.
Primary Outcome
Effects of 1 and 2 years of treatment with isoflavones on percent of changes in FGBT%.
Interventions
- DIETARY_SUPPLEMENT isoflavones
- DIETARY_SUPPLEMENT carbohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2004-04 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
What the finished NCT00204490 record still lists
NCT00204490 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 2 interventions - of which isoflavones is the first listed.
NCT00204490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00204490 about?
NCT00204490 is a clinical study titled "Soy Isoflavones and Breast Cancer Risk Reduction". Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are currently unclear. Breast density has been considered as a breast cancer risk marker. We hypothesize ...
What is the current status of trial NCT00204490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2004-04. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT00204490?
The interventions under investigation include: isoflavones (DIETARY_SUPPLEMENT), carbohydrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00204490?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00204490's enrollment target sits among peer trials
197 349th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia